BEAM:NSD-Beam Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 72.56

Change

-0.12 (-0.17)%

Market Cap

USD 5.39B

Volume

0.72M

Avg Analyst Target

USD 130.40 (+79.71%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Beam Therapeutics Inc (BEAM) Stock Analysis:
Based on the Beam Therapeutics Inc stock forecasts from 4 analysts, the average analyst target price for Beam Therapeutics Inc is USD 130.40 over the next 12 months. Beam Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Beam Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Beam Therapeutics Inc’s stock price was USD 72.56. Beam Therapeutics Inc’s stock price has changed by -9.35 % over the past week, -24.14 % over the past month and +24.08 % over the last year.

About

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-9.12 (-2.94%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

-0.99 (-0.30%)

USD85.30B 11.13 8.07
REGN Regeneron Pharmaceuticals Inc

+3.41 (+0.54%)

USD70.38B 10.09 8.03
VRTX Vertex Pharmaceuticals Incorpo..

-0.55 (-0.27%)

USD48.34B 24.59 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-6.11 (-1.74%)

USD33.10B N/A N/A
SGEN Seagen Inc

+0.42 (+0.27%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.54 (-1.42%)

USD25.19B 58.75 6.30
ALNY Alnylam Pharmaceuticals Inc

+2.92 (+1.62%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BEAM

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.40% 65% D 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.40% 65% D 30% F
Trailing 12 Months  
Capital Gain 24.08% 80% B- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.08% 80% B- 66% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 126.55% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 126.55% 90% A- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 153.07% 17% F 10% F
Risk Adjusted Return 82.67% 96% A 88% B+
Market Capitalization 5.39B 95% A 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 99% A+ 98% A+
Price/Book Ratio 6.13 22% F 21% F
Price / Cash Flow Ratio -56.33 92% A- 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -76.17% 37% F 21% F
Return on Invested Capital -73.83% 29% F 11% F
Return on Assets -32.22% 35% F 10% F
Debt to Equity Ratio 2.16% 71% C- 83% B
Technical Ratios  
Short Ratio 11.66 16% F 7% F
Short Percent 10.75% 16% F 15% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector